.After raising $170 million back in February, metabolic disease-focused BioAge Labs has actually filed to debut on the public market.The Eli Lilly-partnered biotech want to list on the Nasdaq under the symbol "BIOA," according to files filed with the Stocks and Exchange Commission. The provider has not publicly discussed an anticipated financial amount for the offering.The clinical-stage provider proclaims lead prospect azelaprag, a by mouth provided tiny particle slated to get in period 2 screening in combination along with semaglutide-- marketed through Novo Nordisk under brand name Wegovy for weight management-- in the first fifty percent of following year. Semaglutide is actually also marketed as Ozempic as well as Rybelsus through Novo for diabetes.
Apelin receptor agonist azelaprag is actually designed to blend properly with GLP-1 medicines, increasing weight-loss while preserving muscle mass. The investigational drug was actually located to be well-tolerated among 265 people throughout 8 period 1 trials, according to BioAge.Earlier, BioAge got the help of Lilly to run a test mixing azelaprag along with the Large Pharma's GLP-1/ GIP receptor agonist tirzepatide, which is actually industried for diabetes mellitus as Mounjaro as well as Zepbound for weight management. The partners are presently conducting a phase 2 test of azelaprag and also tirzepatide, with topline outcomes expected in the 3rd fourth of 2025.The biotech is additionally considering an insulin sensitivity proof-of-concept test examining azelaprag as a monotherapy in the first one-half of upcoming year to assist prospective sign expansion. In addition, the business intends to ask the FDA for approval in the 2nd half of 2025 to launch individual screening for an NLRP3 prevention targeting metabolic health conditions as well as neuroinflammation.BioAge's foreseed transfer to everyone market follows a small uptick in considered biotech IPOs coming from Bicara Rehabs and also Zenas Biopharma. Zooming out, the current IPO landscape is a "mixed picture," with premium business still debuting on the public markets, merely in lowered amounts, depending on to PitchBook.